AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04609137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management.
Study NCT04609137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drain removal
Description: Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection
Study NCT04597567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal removal
Description: Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
Study NCT01679743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
Study NCT01679743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN 1005
Description: GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
Study NCT00881166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + topotecan
Description: Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
Study NCT00881166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + docetaxel
Description: Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
Study NCT00881166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + erlotinib
Description: 150 mg PO once daily at least 1 hour before or 2 hours after eating
Study NCT00881166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + paclitaxel/carboplatin
Description: Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
Study NCT00881166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + carboplatin/etoposide
Description: Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
Study NCT03555162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Imaging examination
Study NCT03427411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
Study NCT03405311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivanna Accuro 3D Ultrasound Device
Description: The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
Study NCT03405311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
Study NCT04625036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single passive leg movement
Description: The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds.
Study NCT02243748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive individualized palliative care
Study NCT02243748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02243748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02243748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02243748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02224417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Educational Program (DEP)
Description: Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic.
Study NCT02224417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DEP + Process Incentive
Description: Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~* SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~* SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~* SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit.
Study NCT02224417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DEP + Outcome Incentive
Description: Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~* SGD 2 weekly if one glucose readings falls within the normal range,~* SGD 7 weekly if two glucose readings fall within the normal range,~* SGD 14 weekly if all three glucose readings fall within the normal range.
Study NCT00606008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
Study NCT02106481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Catheters
Description: Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)
Study NCT02106481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Shot Femoral Nerve Blocks
Description: The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
Study NCT01715831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
Study NCT01715831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
Study NCT02111018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb Device
Study NCT02111018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Study NCT02548871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program
Description: TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
Study NCT00547339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT)- 45 Gy
Description: Dose of SBRT - 45 Gray (Gy) in five fractions
Study NCT00547339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 47.5 Gy
Description: Dose of SBRT - 47.5 Gray (Gy) in five fractions
Study NCT00547339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
Study NCT00547339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)
Study NCT01248455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Anti-KIR)
Description: Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Study NCT03829176 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
Study NCT02517619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic Solution
Description: 40 mg/mL
Study NCT02517619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate Ophthalmic (1%)
Description: Prednisolone Acetate (1%)
Study NCT01353534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Antigen
Description: A/H5N1 Antigen
Study NCT01353534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine Enhancement Patch
Description: Vaccine Enhancement Patch
Study NCT01632319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Motivational Interviewing and Cognitive Behavioral Therapy
Description: 8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms
Study NCT01632319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
Study NCT03366753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
Study NCT03366753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-vitro hemodilution
Description: Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
Study NCT02271451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q collar
Description: collar worn around neck
Study NCT00977197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
Study NCT00977197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo will be administered twice a day
Study NCT03568201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
Study NCT03568201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
Study NCT04117022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DVS supplementation
Description: Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
Study NCT03074695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE)
Description: Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
Study NCT03074695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Epidural (EPL)
Description: Standard epidural placement
Study NCT03074695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE)
Description: Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
Study NCT03074695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Epidural (EPL)
Description: Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
Study NCT00470548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
Study NCT00470548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
Study NCT03168373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: language rehabilitation therapy
Description: language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
Study NCT03168373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: language rehabilitation therapy
Description: language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
Study NCT03236454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC-Stimulator MC, NeuroConn
Description: 20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
Study NCT03236454 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator MC, NeuroConn
Description: 20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
Study NCT00158353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GirlPOWER! mentoring program
Description: GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
Study NCT00158353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mentoring
Description: Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
Study NCT02897349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02897349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Study NCT02897349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: background therapy
Description: insulin with or without metformin
Study NCT02897349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: background therapy
Description: insulin with or without metformin
Study NCT02158897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolon diet
Description: 3 cycles of a 5-day Prolon diet very month
Study NCT01854814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
Study NCT01854814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Maximum tolerated labeled dose of Losartan
Study NCT01420159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
Study NCT01420159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methoxyflurane
Description: Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
Study NCT00586560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kareniticin and cyclophosphamide
Description: An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.
Study NCT02789371 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: the first pass is made with 5ml suction technique
Description: the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.